Loading…
Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients
The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university...
Saved in:
Published in: | European journal of clinical microbiology & infectious diseases 2011, Vol.30 (1), p.103-108 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953 |
---|---|
cites | cdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953 |
container_end_page | 108 |
container_issue | 1 |
container_start_page | 103 |
container_title | European journal of clinical microbiology & infectious diseases |
container_volume | 30 |
creator | Conde-Estévez, D Grau, S Albanell, J Terradas, R Salvadó, M Knobel, H |
description | The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS > 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia. |
doi_str_mv | 10.1007/s10096-010-1029-5 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_888093943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>888093943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</originalsourceid><addsrcrecordid>eNqFkl1rFTEQhoMotlZ_gDcaBPFqNZOPzeZSDvUDCl5or0NONtum7CbHZLfS3-KfdU732IKC3iSEeeadmXdCyHNgb4Ex_a7iadqGAWuAcdOoB-QYpFCNFFo8JMfMCNkYzcUReVLrFcOcTuvH5IgzDaCNOiY_N2NM0buR-ktXnJ9DiXWOvlKXepqX2ecpVJoHunNzDGmu9EecL-m1Sxi58TE1dak-7Oa4HQM9TSiQffZ-qXRwAYXjKvVXJC4T3d4WdGGKjsZEPYqGclfpKXk0uLGGZ4f7hJx_OP22-dScffn4efP-rPFStXPTSW50DxyUVxoNYQDcd32QwHzoghC9CZ2TimnXq95Jvx3QLe5b0fbBGyVOyJtVd1fy9yXU2U4RRxpHl0Jequ26Dp00UvyfhFYbiS4j-eoP8iovJeEYe0gYoYAhBCvkS661hMHuSpxcubHA7H7Ddt2wZbdvbuy-2RcH4WU7hf4u4_dKEXh9AFxF-4eCpsZ6z4lOSNECcnzlKobSRSj3Hf6r-ss1aXDZugv8K_b8K2cgGBi8DIhfWCTJhA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>816393510</pqid></control><display><type>article</type><title>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</title><source>Springer Nature</source><creator>Conde-Estévez, D ; Grau, S ; Albanell, J ; Terradas, R ; Salvadó, M ; Knobel, H</creator><creatorcontrib>Conde-Estévez, D ; Grau, S ; Albanell, J ; Terradas, R ; Salvadó, M ; Knobel, H</creatorcontrib><description>The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS > 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia.</description><identifier>ISSN: 0934-9723</identifier><identifier>EISSN: 1435-4373</identifier><identifier>DOI: 10.1007/s10096-010-1029-5</identifier><identifier>PMID: 20711795</identifier><language>eng</language><publisher>Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag</publisher><subject>Aged ; Aged, 80 and over ; Anti-Bacterial Agents - administration & dosage ; Anti-Bacterial Agents - pharmacology ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacteremia - drug therapy ; Bacteremia - epidemiology ; Bacteremia - microbiology ; Bacteremia - pathology ; Bacterial diseases ; Bacterial sepsis ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Brief Report ; Cancer therapies ; Enterococcus faecalis ; Enterococcus faecalis - drug effects ; Enterococcus faecalis - isolation & purification ; Enterococcus faecium ; Enterococcus faecium - drug effects ; Enterococcus faecium - isolation & purification ; Epidemiology ; Female ; Gram-Positive Bacterial Infections - drug therapy ; Gram-Positive Bacterial Infections - epidemiology ; Gram-Positive Bacterial Infections - microbiology ; Gram-Positive Bacterial Infections - pathology ; Hospitals ; Hospitals, University ; Human bacterial diseases ; Humans ; Infectious diseases ; Intensive care ; Internal Medicine ; Male ; Medical Microbiology ; Medical sciences ; Middle Aged ; Mortality ; Multivariate analysis ; Neoplasms - complications ; Nosocomial infections ; Pathogens ; Patients ; Penicillin ; Pharmacology. Drug treatments ; Pharmacy ; Physiology ; Regression analysis ; Retrospective Studies ; Risk Factors ; Severity of Illness Index ; Spain - epidemiology ; Treatment Outcome</subject><ispartof>European journal of clinical microbiology & infectious diseases, 2011, Vol.30 (1), p.103-108</ispartof><rights>Springer-Verlag 2010</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</citedby><cites>FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23834361$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20711795$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Conde-Estévez, D</creatorcontrib><creatorcontrib>Grau, S</creatorcontrib><creatorcontrib>Albanell, J</creatorcontrib><creatorcontrib>Terradas, R</creatorcontrib><creatorcontrib>Salvadó, M</creatorcontrib><creatorcontrib>Knobel, H</creatorcontrib><title>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</title><title>European journal of clinical microbiology & infectious diseases</title><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><description>The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS > 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacteremia - drug therapy</subject><subject>Bacteremia - epidemiology</subject><subject>Bacteremia - microbiology</subject><subject>Bacteremia - pathology</subject><subject>Bacterial diseases</subject><subject>Bacterial sepsis</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brief Report</subject><subject>Cancer therapies</subject><subject>Enterococcus faecalis</subject><subject>Enterococcus faecalis - drug effects</subject><subject>Enterococcus faecalis - isolation & purification</subject><subject>Enterococcus faecium</subject><subject>Enterococcus faecium - drug effects</subject><subject>Enterococcus faecium - isolation & purification</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Gram-Positive Bacterial Infections - drug therapy</subject><subject>Gram-Positive Bacterial Infections - epidemiology</subject><subject>Gram-Positive Bacterial Infections - microbiology</subject><subject>Gram-Positive Bacterial Infections - pathology</subject><subject>Hospitals</subject><subject>Hospitals, University</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Intensive care</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medical Microbiology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Multivariate analysis</subject><subject>Neoplasms - complications</subject><subject>Nosocomial infections</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Penicillin</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacy</subject><subject>Physiology</subject><subject>Regression analysis</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Spain - epidemiology</subject><subject>Treatment Outcome</subject><issn>0934-9723</issn><issn>1435-4373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkl1rFTEQhoMotlZ_gDcaBPFqNZOPzeZSDvUDCl5or0NONtum7CbHZLfS3-KfdU732IKC3iSEeeadmXdCyHNgb4Ex_a7iadqGAWuAcdOoB-QYpFCNFFo8JMfMCNkYzcUReVLrFcOcTuvH5IgzDaCNOiY_N2NM0buR-ktXnJ9DiXWOvlKXepqX2ecpVJoHunNzDGmu9EecL-m1Sxi58TE1dak-7Oa4HQM9TSiQffZ-qXRwAYXjKvVXJC4T3d4WdGGKjsZEPYqGclfpKXk0uLGGZ4f7hJx_OP22-dScffn4efP-rPFStXPTSW50DxyUVxoNYQDcd32QwHzoghC9CZ2TimnXq95Jvx3QLe5b0fbBGyVOyJtVd1fy9yXU2U4RRxpHl0Jequ26Dp00UvyfhFYbiS4j-eoP8iovJeEYe0gYoYAhBCvkS661hMHuSpxcubHA7H7Ddt2wZbdvbuy-2RcH4WU7hf4u4_dKEXh9AFxF-4eCpsZ6z4lOSNECcnzlKobSRSj3Hf6r-ss1aXDZugv8K_b8K2cgGBi8DIhfWCTJhA</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Conde-Estévez, D</creator><creator>Grau, S</creator><creator>Albanell, J</creator><creator>Terradas, R</creator><creator>Salvadó, M</creator><creator>Knobel, H</creator><general>Berlin/Heidelberg : Springer-Verlag</general><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</title><author>Conde-Estévez, D ; Grau, S ; Albanell, J ; Terradas, R ; Salvadó, M ; Knobel, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacteremia - drug therapy</topic><topic>Bacteremia - epidemiology</topic><topic>Bacteremia - microbiology</topic><topic>Bacteremia - pathology</topic><topic>Bacterial diseases</topic><topic>Bacterial sepsis</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brief Report</topic><topic>Cancer therapies</topic><topic>Enterococcus faecalis</topic><topic>Enterococcus faecalis - drug effects</topic><topic>Enterococcus faecalis - isolation & purification</topic><topic>Enterococcus faecium</topic><topic>Enterococcus faecium - drug effects</topic><topic>Enterococcus faecium - isolation & purification</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Gram-Positive Bacterial Infections - drug therapy</topic><topic>Gram-Positive Bacterial Infections - epidemiology</topic><topic>Gram-Positive Bacterial Infections - microbiology</topic><topic>Gram-Positive Bacterial Infections - pathology</topic><topic>Hospitals</topic><topic>Hospitals, University</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Intensive care</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medical Microbiology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Multivariate analysis</topic><topic>Neoplasms - complications</topic><topic>Nosocomial infections</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Penicillin</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacy</topic><topic>Physiology</topic><topic>Regression analysis</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Spain - epidemiology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Conde-Estévez, D</creatorcontrib><creatorcontrib>Grau, S</creatorcontrib><creatorcontrib>Albanell, J</creatorcontrib><creatorcontrib>Terradas, R</creatorcontrib><creatorcontrib>Salvadó, M</creatorcontrib><creatorcontrib>Knobel, H</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical microbiology & infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Conde-Estévez, D</au><au>Grau, S</au><au>Albanell, J</au><au>Terradas, R</au><au>Salvadó, M</au><au>Knobel, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients</atitle><jtitle>European journal of clinical microbiology & infectious diseases</jtitle><stitle>Eur J Clin Microbiol Infect Dis</stitle><addtitle>Eur J Clin Microbiol Infect Dis</addtitle><date>2011</date><risdate>2011</risdate><volume>30</volume><issue>1</issue><spage>103</spage><epage>108</epage><pages>103-108</pages><issn>0934-9723</issn><eissn>1435-4373</eissn><abstract>The purpose of this investigation was to compare the risk factors, clinical features and outcomes in cancer patients with bacteraemia caused by vancomycin-susceptible Enterococcus faecalis and E. faecium. A retrospective, observational 7-year study was carried out in a 450-bed, acute-care university-affiliated hospital. We performed univariate comparisons between the two groups and then multivariate analysis to identify patient risk factors for E. faecium isolation. Seventy-three patients were included in the analysis: 54 (74.0%) with bacteraemia caused by E. faecalis and 19 (26.0%) by E. faecium. The Simplified Acute Physiological Score (SAPS) value was significantly greater in E. faecium isolates (40.7 vs. 35.2; p = 0.009). Diabetes mellitus was more frequently diagnosed in patients with E. faecium bacteraemia (52.6% vs. 24.1%; p = 0.021). Prior penicillin exposure was more frequent in patients with E. faecium bacteraemia (68.4% vs. 29.6%; p = 0.003). There was a trend toward higher mortality in E. faecium bacteraemia patients (47.4% vs. 25.9%; p = 0.084). Independent patient risk factors for E. faecium isolation were prior penicillin exposure (odds ratio [OR], 6.479; p = 0.003) and SAPS > 34 (OR, 6.896; p = 0.009). When compared to E. faecalis bacteraemia, E. faecium bacteraemia in cancer patients is independently associated with more severe illness and prior use of penicillins; therefore, empiric treatment which would cover E. faecium should be considered in cancer patients suspected of having bacteraemia.</abstract><cop>Berlin/Heidelberg</cop><pub>Berlin/Heidelberg : Springer-Verlag</pub><pmid>20711795</pmid><doi>10.1007/s10096-010-1029-5</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0934-9723 |
ispartof | European journal of clinical microbiology & infectious diseases, 2011, Vol.30 (1), p.103-108 |
issn | 0934-9723 1435-4373 |
language | eng |
recordid | cdi_proquest_miscellaneous_888093943 |
source | Springer Nature |
subjects | Aged Aged, 80 and over Anti-Bacterial Agents - administration & dosage Anti-Bacterial Agents - pharmacology Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Bacteremia - drug therapy Bacteremia - epidemiology Bacteremia - microbiology Bacteremia - pathology Bacterial diseases Bacterial sepsis Biological and medical sciences Biomedical and Life Sciences Biomedicine Brief Report Cancer therapies Enterococcus faecalis Enterococcus faecalis - drug effects Enterococcus faecalis - isolation & purification Enterococcus faecium Enterococcus faecium - drug effects Enterococcus faecium - isolation & purification Epidemiology Female Gram-Positive Bacterial Infections - drug therapy Gram-Positive Bacterial Infections - epidemiology Gram-Positive Bacterial Infections - microbiology Gram-Positive Bacterial Infections - pathology Hospitals Hospitals, University Human bacterial diseases Humans Infectious diseases Intensive care Internal Medicine Male Medical Microbiology Medical sciences Middle Aged Mortality Multivariate analysis Neoplasms - complications Nosocomial infections Pathogens Patients Penicillin Pharmacology. Drug treatments Pharmacy Physiology Regression analysis Retrospective Studies Risk Factors Severity of Illness Index Spain - epidemiology Treatment Outcome |
title | Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patients |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T00%3A05%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20characteristics%20and%20outcomes%20of%20patients%20with%20vancomycin-susceptible%20Enterococcus%20faecalis%20and%20Enterococcus%20faecium%20bacteraemia%20in%20cancer%20patients&rft.jtitle=European%20journal%20of%20clinical%20microbiology%20&%20infectious%20diseases&rft.au=Conde-Est%C3%A9vez,%20D&rft.date=2011&rft.volume=30&rft.issue=1&rft.spage=103&rft.epage=108&rft.pages=103-108&rft.issn=0934-9723&rft.eissn=1435-4373&rft_id=info:doi/10.1007/s10096-010-1029-5&rft_dat=%3Cproquest_cross%3E888093943%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c456t-84297d1215c570090112c8de410ce8e33d9e8a4507ad5da4cbf1022c636dec953%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=816393510&rft_id=info:pmid/20711795&rfr_iscdi=true |